Bempikibart Phase 2a in Severe Alopecia Areata (SIGNAL-AA)

Market
100%75%50%25%0%Apr 26 • YES 37.0%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
6/1/26
Study Completion
9/1/26
Sponsor
Q32 Bio Inc.
Ticker
$QTTB
Type
Phase 2
Trial Status
Active Not Recruiting
Trial Size
75
NCT
NCT06018428
Trial Description
Phase 2 proof-of-concept study of subcutaneous bempikibart (ADX-914) in adults with severe alopecia areata. Part A was randomized, double-blind, and placebo-controlled and has completed participation; Part B is an ongoing multicenter open-label study assessing efficacy, safety, and tolerability.